An FDA advisory panel will be asked to vote on whether a diabetes drug made by Eli Lilly and Boehringer Ingelheim cuts the risk of cardiovascular death, according to the agency's website.
- Celgene Snaps Up Merck & Co.’s Giant Complex in New Jersey 6,800 views
- Top 10 Pipelines 4,566 views
- Annual Report: Top 10 Pipelines 4,100 views
- Top 100 Biotechnology Companies Special Report: The Acquisition Game 2,500 views